Cambridge-based biotech CardiaTec, which uses computational biology to discover new treatments for cardiovascular disease, has secured $6.5 million in seed funding led by Montage Ventures, with participation from Continuum Health Ventures, Laidlaw Ventures, and APEX Ventures. The new funding will enable CardiaTec to advance proprietary drug targets to the preclinical stage.
- Founded in 2021 by Namshik Han, Thelma Zablocki, and Raphael Peralta, CardiaTec is developing the largest human cardiac tissue multi-omics database by leveraging its extensive hospital and academic network.
- The startup utilizes large-scale multi-omics data to gain new insights into cardiovascular disease biology and accelerate the discovery of novel therapeutic targets for innovative treatments.
Details of the deal
- The fresh round was led by California-based Montage Ventures, an early-stage venture capital firm that invests in startups across sectors such as financial services, healthcare, and commerce.
- The funding round also received support from Toronto-based VC Continuum Health Ventures, London-based VC Laidlaw Ventures, APEX Ventures, and several business angels, including Dr. Maximilien Levesque and Naheed Kurji.
- With the capital raised, CardiaTec plans to expand its platform and advance its proprietary drug targets to the preclinical stage.
